192 related articles for article (PubMed ID: 36536402)
1. HNRNPC, a predictor of prognosis and immunotherapy response based on bioinformatics analysis, is related to proliferation and invasion of NSCLC cells.
Gu Z; Yang Y; Ma Q; Wang H; Zhao S; Qi Y; Li Y
Respir Res; 2022 Dec; 23(1):362. PubMed ID: 36536402
[TBL] [Abstract][Full Text] [Related]
2. Serum-derived extracellular vesicles promote the growth and metastasis of non-small cell lung cancer by delivering the m6A methylation regulator HNRNPC through the regulation of DLGAP5.
Shi S; Wu T; Ma Z; Zhang X; Xu K; Tian Q; Gao L; Yin X; Xu S; Yang S
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4639-4651. PubMed ID: 36175801
[TBL] [Abstract][Full Text] [Related]
3. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
5. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
6. M6A-related bioinformatics analysis reveals that HNRNPC facilitates progression of OSCC via EMT.
Huang GZ; Wu QQ; Zheng ZN; Shao TR; Chen YC; Zeng WS; Lv XZ
Aging (Albany NY); 2020 Jun; 12(12):11667-11684. PubMed ID: 32526707
[TBL] [Abstract][Full Text] [Related]
7. RNA-binding protein KHSRP promotes tumor growth and metastasis in non-small cell lung cancer.
Yan M; Sun L; Li J; Yu H; Lin H; Yu T; Zhao F; Zhu M; Liu L; Geng Q; Kong H; Pan H; Yao M
J Exp Clin Cancer Res; 2019 Nov; 38(1):478. PubMed ID: 31775888
[TBL] [Abstract][Full Text] [Related]
8. Analysis and validation of m6A regulatory network: a novel circBACH2/has-miR-944/HNRNPC axis in breast cancer progression.
Lv W; Tan Y; Xiong M; Zhao C; Wang Y; Wu M; Wu Y; Zhang Q
J Transl Med; 2021 Dec; 19(1):527. PubMed ID: 34952600
[TBL] [Abstract][Full Text] [Related]
9. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
10. HNRNPC suppresses tumor immune microenvironment by activating Treg cells promoting the progression of prostate cancer.
Cheng Y; Li L; Wei X; Xu F; Huang X; Qi F; Zhang Y; Li X
Cancer Sci; 2023 May; 114(5):1830-1845. PubMed ID: 36718950
[TBL] [Abstract][Full Text] [Related]
11. Methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit-induced long intergenic non-protein coding RNA 1833 N6-methyladenosine methylation promotes the non-small cell lung cancer progression via regulating heterogeneous nuclear ribonucleoprotein A2/B1 expression.
Li D; Fu Z; Dong C; Song Y
Bioengineered; 2022 Apr; 13(4):10493-10503. PubMed ID: 35441574
[TBL] [Abstract][Full Text] [Related]
12. The m6A reader HNRNPC predicts adverse prognosis and promotes the progression of colorectal cancer.
Yu YM; Hu Y
Technol Health Care; 2024; 32(3):1445-1453. PubMed ID: 37661903
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
14. N6-methylation of RNA-bound adenosine regulator HNRNPC promotes vascular endothelial dysfunction in type 2 diabetes mellitus by activating the PSEN1-mediated Notch pathway.
Cai Y; Chen T; Wang M; Deng L; Li C; Fu S; Xie K
Diabetes Res Clin Pract; 2023 Mar; 197():110261. PubMed ID: 36681355
[TBL] [Abstract][Full Text] [Related]
15. HNRNPC promotes collagen fiber alignment and immune evasion in breast cancer via activation of the VIRMA-mediated TFAP2A/DDR1 axis.
Lian B; Yan S; Li J; Bai Z; Li J
Mol Med; 2023 Aug; 29(1):103. PubMed ID: 37528369
[TBL] [Abstract][Full Text] [Related]
16. Four m6A RNA Methylation Gene Signatures and Their Prognostic Values in Lung Adenocarcinoma.
Wang Y; Zhao X; Li J; Wang X; Hu W; Zhang X
Technol Cancer Res Treat; 2022; 21():15330338221085373. PubMed ID: 35343834
[No Abstract] [Full Text] [Related]
17. HNRNPC promotes estrogen receptor-positive breast cancer cell cycle by stabilizing WDR77 mRNA in an m6A-dependent manner.
Xu W; Huang Z; Xiao Y; Li W; Xu M; Zhao Q; Yi P
Mol Carcinog; 2024 May; 63(5):859-873. PubMed ID: 38353359
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis of the correlation between m6A RNA methylation regulators and the immune infiltration and prognosis of bladder cancer.
Wu J; Wang X; Xu H; Tian J; Ji H; Zhu J; Guo H; Chen Z
Ann Transl Med; 2022 Dec; 10(24):1386. PubMed ID: 36660722
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a N6 methylation regulator-related gene signature for prognostic and immune response prediction in non-small cell lung cancer.
Li X; Ma J; Sun Z; Li N; Jiao G; Zhang T; Cao H
Am J Cancer Res; 2023; 13(7):2984-2997. PubMed ID: 37560004
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value and multiomic features of m6A-related risk signature in lung adenocarcinoma.
Wang X; Yu Q; Yu H; Wang Y; Sun L; Yu L; Cui H; Yang H
Am J Transl Res; 2022; 14(8):5379-5393. PubMed ID: 36105012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
